AdAlta

Webinars

Updates

Home

Why Invest

Announcements

Lora

In this webinar presentation, Dr Oldham discusses the results of AdAlta’s strategic review and portfolio prioritization announced separately today, including:

What drives AdAlta’s “East to West” cellular immunotherapy strategy

How the “East to West” strategy will be AdAlta’s key driver of future pipeline growth and value creation

Recent progress made in executing the “East to West” strategy, including the signing of term sheets conferring exclusive negotiation rights

How the value inherent in AdAlta’s fibrosis disease drug candidate AD-214 will be monetised.

Webinar presentation - East to West cell therapy strategy

Announcement summary